Articles tagged with Cervical Cancer
A study by Monash University found a significant reduction in all four HPV genotypes in gay/bisexual men after implementing the school-based HPV vaccination program. The results suggest that male vaccination may lead to a potential reduction in anal cancer among gay and bisexual men in Australia.
A recent study found that only 19% of women in sub-Saharan Africa underwent cervical cancer screenings between 2011 and 2018. The rates varied greatly by country, with some countries having nearly 46% of women screened versus less than 1%. Increasing screenings is crucial to detect the disease early and improve treatment outcomes.
A new study found a substantial decrease in minimally invasive surgery use for cervical cancer after the publication of a major study in 2018. The study assessed 2,437 patients and showed that surgeons changed their methods, but still saw room for improvement at non-academic medical centers.
A recent study found that only 16% of male teenagers received the HPV vaccine, highlighting a significant gap in vaccination rates. The vaccine is essential for preventing oropharyngeal cancer, which affects 80% of male patients diagnosed with this condition.
Researchers found that brachytherapy can proceed without delay or antibiotics in cervical cancer patients with uterine perforations, reducing treatment complications. The study suggests this approach could lead to a new standard of care and improved survival rates for these patients.
Researchers have created the first patient-derived organoid model for cervical cancer, allowing them to study human papillomavirus (HPV) and its impact on cervical tissue. The model's success holds promise for advancing research into cervical biology and associated diseases.
A study found that adequate levels of five antioxidants may reduce infection with high-risk human papillomavirus (HPV) strains associated with cervical cancer. Lower levels of serum albumin and four dietary antioxidants were linked to a higher risk of HPV infection, suggesting a potential nutritional strategy for prevention.
Emerging technologies can screen for cervical cancer better than Pap smears, especially in places with limited access to healthcare. Advanced nanotechnology and computer learning are helping develop HPV screening that takes the guesswork out of precancer tests.
A study of over 150,000 European women has identified PAX8, CLPTM1L, and HLA region gene variants associated with an increased risk of developing cervical cancer. The findings open avenues for personalized screening approaches or targeted treatments.
The conference explored updates to NCCN Clinical Practice Guidelines, new research, and strategies for preventing HPV-associated cancers. Experts discussed ways to improve racial equity in cancer care, including reducing disparities and promoting guideline-adherent care.
Research from Michigan State University highlights the racial disparity gap in cervical cancer information and follow-up, citing poor provider-patient communication as a key factor. The study suggests that improving education and using digital channels like text messages can help bridge this gap.
A new AI-powered screening tool has been developed to detect precursors to cervical cancer in women, particularly in low-income countries where access to skilled pathologists and advanced equipment is limited. The method uses mobile digital microscopy and achieves a sensitivity of 96-100% in identifying patients with precancerous lesions.
A new study found that vaccinating adults age 26 and older against HPV may not provide significant health benefits, due to high costs and lower vaccine efficacy in older individuals. Cervical cancer screening remains an effective way to protect women from cervical cancer.
The journal's publication outlines targets for HPV vaccination, screening and treatment to achieve 90%, 70% and 90% coverage respectively. The World Health Organization strategy aims to eliminate cervical cancer globally by 2030.
A special issue of Preventive Medicine outlines courses of action to eliminate cervical cancer through HPV vaccination, screening, and treatment. The WHO strategy aims for 90% HPV vaccination coverage, 70% screening coverage, and 90% access to treatment by 2030.
A new study from the University of Minnesota Medical School found that Pap test samples can detect proteins also present in ovarian cancer tumor tissues. This discovery suggests potential biomarker candidates for early detection of ovarian cancer, which currently has no early warning system.
A new study published in The Lancet Global Health found that cervical cancer risk is six times higher in HIV-infected women worldwide. Southern and Eastern Africa are particularly affected due to high rates of HIV and Human Papillomavirus (HPV) infections.
Researchers at UCLA have discovered a gene called PACS-1 that is overexpressed in cancer tissues, which can lead to cancer growth and spread. Higher levels of PACS-1 expression in the nucleus may indicate resistance to chemotherapy and radiation treatments.
Researchers found that women with low levels of senescence-associated secreted phenotypes (SASPs) had higher survival rates than those with high levels. Brachytherapy greatly improved survival in patients with high SASP levels, but had little impact on those with low levels.
A large study by Karolinska Institutet found that HPV vaccination significantly reduces the risk of cervical cancer. Women vaccinated at a young age show a 88% reduced risk, while those vaccinated between ages 17 and 30 experience a halved risk.
A comprehensive genomic study of cervical cancers in sub-Saharan Africa has identified unique features associated with HIV-positive and HIV-negative patients. The study found distinct gene expression patterns for HPV types and epigenetic changes linked to aggressive tumors, providing potential treatment options.
A recent study published in Nature Genetics analyzed genomic differences between HPV strains causing cervical cancers, revealing distinct characteristics and implications for prognosis. The researchers identified specific patterns associated with aggressive cancers, highlighting the need for further studies on African populations.
Researchers developed a novel three-dimensional imaging system that uses near-infrared light to diagnose cervical cancer faster and non-invasively than conventional methods. The system analyzes tissue biopsies in real-time without histopathological preparation, improving diagnosis accuracy and turnaround time.
A literature review found significant evidence supporting the causal role of high-risk HPV types 16 and 18 in prostate cancer. The authors suggest that HPV vaccination may help prevent prostate cancer development, particularly in countries with high mortality rates from cervical cancer.
A UCLA-led study found that school HPV vaccine policies in Rhode Island and the District of Columbia significantly increased vaccination rates among adolescents. The expansion of such policies could lead to higher vaccination rates and reduced cancer risk, particularly for cervical, oral, and rectal cancers.
The new recommendations emphasize more precise management based on estimates of a patient's risk, enabling personalized diagnoses, treatments, and follow-ups. Patients with higher individualized risk estimates require more frequent screening, colposcopy/biopsy, and treatment.
Patients with cervical cancer who produce antibodies targeting specific sugars on their cells appear to fare better when treated with internal radiation therapy. These antibodies also indicate a generally high immune competency, making them an indirect marker of antitumor immunity.
A multilevel intervention program improved HPV vaccination series initiation and completion rates among adolescent patients. The program educated pediatric and family medicine providers about the importance of HPV vaccines, along with healthcare system changes that started the HPV vaccine series before age 11.
A study combining 15 observational studies with 9,500 patients compared the risk of cancer recurrence and death associated with minimally invasive versus open radical hysterectomy for early-stage cervical cancer. The results showed no significant difference in overall survival between the two groups.
A meta-analysis of 15 studies found that minimally invasive radical hysterectomy for early-stage cervical cancer is linked to a 71% higher risk of recurrence or death compared to open surgery. The study's findings suggest that the benefits of minimally invasive procedures may not outweigh the risks for this specific type of cancer.
The American Society for Radiation Oncology (ASTRO) has released its first clinical guideline on radiation therapy for cervical cancer. The guidelines address indications and best practices for external beam radiation therapy and brachytherapy in postoperative and definitive settings, including the use of chemotherapy and IMRT.
A new imaging method detects metabolic and structural changes in cervical epithelial cells using intrinsic fluorescence, enabling early-stage bedside diagnosis. This non-invasive approach opens up a routine monitoring strategy for patients at high risk of cervical cancer.
Researchers at the Medical University of South Carolina have discovered a natural product, manzamine A, that exhibits anti-cancer properties in cervical cancer cells. The compound stops cell growth and causes some cells to die, with potential applications for treatment and development.
Cervical cancer screening rates dropped by over 3% in four areas of Miyagi Prefecture after the 2011 Great East Japan Earthquake, with rates still lower five years later. Long-term monitoring is needed to restore screening rates in affected areas.
Combining therapeutic HPV vaccine ISA101 with chemotherapy drugs carboplatin and paclitaxel may extend survival in patients with advanced cervical cancer. The vaccine was well-tolerated, reducing suppressive myeloid cells to better stimulate T cell responses.
A Swedish-Finnish study found that HPV vaccination of both boys and girls prevents infections effectively, even if only 80% of girls are vaccinated. Mathematical modelling shows that vaccinating both genders can eliminate the most oncogenic HPV type 16 in a few years after age 30.
A study found that HPV vaccination rates dropped significantly after the government's suspension of proactive recommendations, leading to potential 5,000 additional deaths. Restoring high-level political support and proactive recommendations could prevent most of this damage.
A single dose of the human papillomavirus (HPV) vaccine is as effective as multiple doses for preventing preinvasive cervical disease, which can later develop into cervical cancer. The risk of preinvasive cervical disease was lower in adolescents who received one, two, or three doses of the HPV vaccine compared to unvaccinated teens.
A new study suggests that scaling up cervical cancer screening coverage in the US to 90% can expedite elimination of the disease and avert more than 1,000 additional cases per year. Increasing HPV vaccination coverage also plays a critical role in reducing cervical cancer burden.
A new study from UNM Comprehensive Cancer Center scientists reveals that cervical cancer screening every three years is protective against cervical cancer. Most cancers are caught before spreading, making treatment easier. Screening was found to reduce localized and distant cancers.
A comprehensive survey of viruses found within cancer cells reveals 23 different virus types in 356 patients, with Epstein-Barr and HPV viruses commonly linked to cancer. The study also identifies mechanisms by which viruses trigger carcinogenic mutations, providing potential avenues for vaccine development.
A recent CMAJ editorial emphasizes the importance of investing in social equity to address health disparities among low-income individuals. The authors highlight the persistent gaps in healthcare access and outcomes according to income, which result from poverty's association with various social determinants of health.
Two new studies quantify the potential for eliminating cervical cancer in 78 low-income and lower-middle income countries, proposing measures to avert 74 million cases and 62 million deaths over the next century. The proposed triple intervention strategy of HPV vaccination, cervical screening, and treatment could reduce mortality by up...
Two studies published in The Lancet conclude that cervical cancer could be eliminated worldwide by the next century, with North America expected to see almost complete eradication by 2040. High vaccination coverage and high uptake of screening and treatment are key to achieving this goal.
A recent Danish study found that vaccine misinformation resulted in a 50.4% drop in HPV vaccination rates, leaving around 26,000 girls unvaccinated and potentially exposing them to 180 avoidable cervical cancer cases and 45 deaths.
A new study by UCSF and CDC estimates that millions of young women in the US are undergoing medically unnecessary pelvic exams and Pap tests. The exams can lead to false positives, over-treatment, anxiety, and unnecessary cost.
Results from NRG-GOG 9929 show that ipilimumab is tolerated in the curative treatment of women with lymph node-positive cervical cancer. The trial found a 12-month progression-free survival rate of 81% and overall survival rate of 90%. Future studies are needed to identify therapeutic targets for improved outcomes.
Anal cancer diagnoses and deaths related to human papillomavirus (HPV) have increased dramatically over the last 15 years, according to researchers at The University of Texas Health Science Center at Houston. The study found that anal cancer rates and mortality rates had more than doubled for people in their 50s and 60s.
Researchers identified Notch as a key molecule involved in cervical cancer progression, contrary to previous thought that Ras was the primary culprit. The review highlights the complex nature of cervical cancer progression, suggesting that local proliferation and metastasis occur through parallel routes.
A study on cancer trends in Canada from 1971 to 2015 found an increase in breast and colorectal cancers among younger adults, particularly women aged 30-39. In contrast, cancer incidence has decreased in older age groups, with declines seen in cervical, lung, bladder, and prostate cancers across most age categories.
A new study published in The American Journal of Pathology suggests that medroxyprogesterone acetate (MPA) is effective in preventing the development of cervical cancer in mice with precancerous lesions. MPA also decreased existing precancerous lesions, offering a non-invasive approach to combat cervical cancer.
A study found that cervical cancer screening rates decline among women aged 45-65, particularly those with lower education, rural residency, or lack of insurance. The study highlights the need for increased awareness and access to screenings for vulnerable populations.
A new study found that mailed self-sampling kits for HPV testing increased cervical cancer screening by 50% in underserved women, with 88% of testers negative for the virus. However, only 70% of women who tested positive followed up for follow-up testing.
Researchers developed a non-invasive test to detect cervical pre-cancer by analyzing urine and vaginal samples collected by women themselves. The test, called S5, measures DNA methylation and has been shown to accurately identify high-risk women with an HPV positive test.
Researchers developed a new approach to detect bacteria and viruses associated with cancers. By sequencing genomic data from tumors, they can identify pathogens linked to diseases such as stomach cancer and cervical cancer. The method holds promise for developing new cancer vaccines in the future.
A school-based HPV vaccination program in British Columbia has significantly reduced cervical pre-cancer rates among women, with a 57% reduction found in those vaccinated as Grade 6 girls compared to unvaccinated women. Regular cervical screening is crucial in preventing cervical cancer from developing.
A new study presents promising results from the CheckMate 358 trial, a phase I/II investigational immune-therapy trial combining nivolumab and ipilimumab for recurrent and metastatic cervical cancer. The combination showed higher clinical benefit rates compared to single-agent treatments.
The closure of nearly 100 women's health clinics in the US was associated with fewer cervical cancer screenings, more advanced diagnoses, and increased mortality rates. States with clinic closures saw a 2% drop in screenings, particularly among uninsured women, Hispanic women, and young adults.
A new diagnostic approach detects high-risk HPV infection and precancerous markers, improving the ability to diagnose cervical cancer in HPV-positive women. The test has a sensitivity of 97.3% and negative predictive value of 93.8%, making it a promising tool for cervical cancer triage.
A new study has found that psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer. Patients who experienced stress-related disorders or stressful life events were 33% more likely to die from the disease compared to those who did not report stress.